Miglitol is an oral anti-diabetic drug that acts by inhibiting carbohydrate absorption in the small intestine. Recent studies have shown that miglitol reduces obesity in humans and rodents. Miglitol’s anti-obesity effect has been attributed to increased energy expenditure by upregulating UCP1 in BAT (i.e., by thermogenesis) and to enhancement of β3-adrenergic signaling in BAT. 

Miglitol an α-glucosidase inhibitor, induces an enhanced and prolonged release of glucagon-like peptide-1, regulating appetite and stabilizing body weight in humans. Miglitol displays anti-atherothrombotic effect by reducing platelet activation and raising circulating adiponectin levels in patients with type 2 diabetes. 

Additional Information

Additional Information